Zhejiang Hisoar Pharmaceutical Co Ltd (002099) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Zhejiang Hisoar Pharmaceutical Co Ltd ¥1.39, price ¥5.63, upside -75.3%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Zhejiang Hisoar Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥4.22 – ¥11.31 · fair‑value band ¥1.21 – ¥1.66 · the ¥5.63 price screens above the ¥1.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Zhejiang Hisoar Pharmaceutical Co in your weekly email
Every Wednesday you see whether Zhejiang Hisoar Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products.
Show more
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical chemical supplies and appliances, and other chemical intermediates. The company was founded in 1966 and is based in Taizhou, China.
Stock analysis
Zhejiang Hisoar Pharmaceutical Co Ltd (002099) currently trades at ¥5.63, while our model-based Fair Value estimate is ¥1.39, implying the stock looks roughly 305.0% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥3.61 per share, and 0 of the 5 models we run sit above the ¥5.63 price.
Bear case: the Dividend Discount group reads lowest at ¥0.2000, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.21 (bear) to ¥1.66 (bull), the price of ¥5.63 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Zhejiang Hisoar Pharmaceutical Co Ltd reported revenue of 1.9B CNY in FY2025 versus 2.5B CNY in FY2021, a compound −7.0%/yr. Reported net income was −91.1M CNY in FY2025.
Key figures
Market cap 9.1B CNY (≈ $1.4B) · P/S ratio 4.58 · EPS (TTM) ¥−0.0500 · Dividend yield 0.3% · Net margin −4.9% · Return on equity −1.5% · Return on assets (EBIT) −1.6% · Operating margin 3.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −75%, 002099 screens richer than that median.
Fair Value models
Bear ¥1.21Fair Value ¥1.39Bull ¥1.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Start year 2020 (pandemic). Over 10 years: −2.8% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.0% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zhejiang Hisoar Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−75% · Bottom 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−4% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth0% · Below median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.27× · Cheapest 25%
P/S (TTM)0.73× · Cheapest 25%
EV/EBITDA0.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 25
HEALTH (low debt)99· sector 96
DIVIDEND (yield)6· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Hisoar Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002099
Frequently asked questions
Is Zhejiang Hisoar Pharmaceutical Co Ltd (002099) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥1.39 versus a price of ¥5.63, about −75% upside (overvalued).
What is the fair value of 002099?
Our model-based fair value for Zhejiang Hisoar Pharmaceutical Co Ltd is ¥1.39 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥5.63.
What is the quality score of 002099?
Zhejiang Hisoar Pharmaceutical Co Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Our model-based price target is the fair value of ¥1.39 (as of Sep 23, 2026) from 5 valuation models. Cautious scenario ¥1.21, optimistic scenario ¥1.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Hisoar Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.39, about −75% upside versus a price of ¥5.63 (overvalued). Cautious scenario ¥1.21, optimistic scenario ¥1.66. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Zhejiang Hisoar Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 1.9B CNY (latest available figure, as of Sep 23, 2026).
Does Zhejiang Hisoar Pharmaceutical Co Ltd pay a dividend?
Zhejiang Hisoar Pharmaceutical Co Ltd currently shows a dividend yield of about 0.31% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Hisoar Pharmaceutical Co Ltd it is ¥1.39 per share (as of Sep 23, 2026), against a price of ¥5.63. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang Hisoar Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 002099 trades above its calculated fair value: price ¥5.63, fair value ¥1.39, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002099?
No. The price is what the market pays today (¥5.63); the fair value is what the company's own numbers justify (¥1.39). For Zhejiang Hisoar Pharmaceutical Co Ltd the two are ¥4.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Hisoar Pharmaceutical Co Ltd worth?
The market values Zhejiang Hisoar Pharmaceutical Co Ltd at about 9.1B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥5.63; our models calculate a fair value of ¥1.39 per share.
What do the bullish and bearish scenarios say about 002099?
Our models span a range for Zhejiang Hisoar Pharmaceutical Co Ltd: cautious scenario ¥1.21, base ¥1.39, optimistic ¥1.66 per share (as of Sep 23, 2026, price ¥5.63). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Balance-sheet figures for Zhejiang Hisoar Pharmaceutical Co Ltd (as of Sep 23, 2026): return on equity −1.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 002099 from its 52-week high?
Zhejiang Hisoar Pharmaceutical Co Ltd trades at ¥5.63, about 36% below its 52-week high of ¥8.83 and 13% above the low of ¥4.98 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.39 is for.
Which stocks are comparable to Zhejiang Hisoar Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Hisoar Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥5.63, calculated fair value ¥1.39 (−75%), Quality Score 51/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002099 calculated?
We run Zhejiang Hisoar Pharmaceutical Co Ltd through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Zhejiang Hisoar Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The closing price on Sep 22, 2026 was ¥5.63. Our model-based fair value is ¥1.39, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Hisoar Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥1.66). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Zhejiang Hisoar Pharmaceutical Co Ltd
How large is the market capitalisation of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The market capitalisation of Zhejiang Hisoar Pharmaceutical Co Ltd is 9.1B CNY (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The price-to-sales ratio of Zhejiang Hisoar Pharmaceutical Co Ltd is 4.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Earnings per share at Zhejiang Hisoar Pharmaceutical Co Ltd are ¥−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The dividend yield of Zhejiang Hisoar Pharmaceutical Co Ltd is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The net margin of Zhejiang Hisoar Pharmaceutical Co Ltd is −4.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The return on equity (ROE) of Zhejiang Hisoar Pharmaceutical Co Ltd is −1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
On an EBIT basis the return on assets of Zhejiang Hisoar Pharmaceutical Co Ltd is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
The operating margin of Zhejiang Hisoar Pharmaceutical Co Ltd is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Zhejiang Hisoar Pharmaceutical Co Ltd (002099)?
Earnings per share at Zhejiang Hisoar Pharmaceutical Co Ltd are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Hisoar Pharmaceutical Co Ltd (002099) generate?
The free cash flow of Zhejiang Hisoar Pharmaceutical Co Ltd is −134M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Hisoar Pharmaceutical Co Ltd (002099) hold?
Zhejiang Hisoar Pharmaceutical Co Ltd holds more cash than debt, 289M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhejiang Hisoar Pharmaceutical Co Ltd in the live analysis
One click puts Zhejiang Hisoar Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
